Liven Pharma Limited (PSX:LIVEN)

Liven Pharma Statistics

Total Valuation

Liven Pharma has a market cap or net worth of PKR 4.37 billion. The enterprise value is 4.22 billion.

Market Cap	4.37B
Enterprise Value	4.22B

Important Dates

The next estimated earnings date is Thursday, November 5, 2026.

Earnings Date	Nov 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Liven Pharma has 113.04 million shares outstanding. The number of shares has increased by 172.01% in one year.

Current Share Class	113.04M
Shares Outstanding	113.04M
Shares Change (YoY)	+172.01%
Shares Change (QoQ)	+40.23%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.13%
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	44.08
PB Ratio	5.28
P/TBV Ratio	5.33
P/FCF Ratio	23.65
P/OCF Ratio	20.14
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.01
EV / Sales	42.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	22.83

Financial Position

The company has a current ratio of 3.79, with a Debt / Equity ratio of 0.03.

Current Ratio	3.79
Quick Ratio	2.27
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	0.15
Interest Coverage	-234.57

Financial Efficiency

Return on equity (ROE) is -81.35% and return on invested capital (ROIC) is -79.66%.

Return on Equity (ROE)	-81.35%
Return on Assets (ROA)	-33.94%
Return on Invested Capital (ROIC)	-79.66%
Return on Capital Employed (ROCE)	-59.04%
Weighted Average Cost of Capital (WACC)	3.08%
Revenue Per Employee	2.42M
Profits Per Employee	-17.10M
Employee Count	41
Asset Turnover	0.10
Inventory Turnover	0.70

Taxes

In the past 12 months, Liven Pharma has paid 57.92 million in taxes.

Income Tax	57.92M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.55% in the last 52 weeks. The beta is -0.24, so Liven Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.24
52-Week Price Change	-33.55%
50-Day Moving Average	36.76
200-Day Moving Average	50.58
Relative Strength Index (RSI)	57.22
Average Volume (20 Days)	110,294

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Liven Pharma had revenue of PKR 99.11 million and -701.22 million in losses. Loss per share was -7.80.

Revenue	99.11M
Gross Profit	8.14M
Operating Income	-532.35M
Pretax Income	-643.30M
Net Income	-701.22M
EBITDA	-505.26M
EBIT	-532.35M
Loss Per Share	-7.80

Balance Sheet

The company has 178.80 million in cash and 27.37 million in debt, with a net cash position of 151.43 million or 1.34 per share.

Cash & Cash Equivalents	178.80M
Total Debt	27.37M
Net Cash	151.43M
Net Cash Per Share	1.34
Equity (Book Value)	827.96M
Book Value Per Share	7.32
Working Capital	225.31M

Cash Flow

In the last 12 months, operating cash flow was 216.89 million and capital expenditures -32.16 million, giving a free cash flow of 184.72 million.

Operating Cash Flow	216.89M
Capital Expenditures	-32.16M
Depreciation & Amortization	27.09M
Net Borrowing	-8.34M
Free Cash Flow	184.72M
FCF Per Share	1.63

Margins

Gross Margin	8.21%
Operating Margin	-537.14%
Pretax Margin	-649.09%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	186.39%

Dividends & Yields

Liven Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-172.01%
Shareholder Yield	-172.01%
Earnings Yield	-16.05%
FCF Yield	4.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Liven Pharma has an Altman Z-Score of 20.24 and a Piotroski F-Score of 3.

Altman Z-Score	20.24
Piotroski F-Score	3